Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Elsevier 2019

Παρόμοια τεκμήρια

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism
ανά: Ho Jin Kim, κ.ά.
Έκδοση: (2023-12-01)

Treatment of Neuromyelitis Optica: Review and Recommendations.
ανά: Kimbrough, D, κ.ά.
Έκδοση: (2012)

Comparison of inebilizumab or rituximab in addition to glucocorticoid therapy for neuromyelitis optica spectrum disorders
ανά: Chu-Yuan Lou, κ.ά.
Έκδοση: (2024-06-01)

Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
ανά: Dominik Lehrieder, κ.ά.
Έκδοση: (2023-11-01)

Treatment of neuromyelitis optica: Review and recommendations
ανά: Kimbrough, D, κ.ά.
Έκδοση: (2012)

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialResearch in context
ανά: Jeffrey L. Bennett, κ.ά.
Έκδοση: (2022-12-01)

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report
ανά: Xuefen Chen, κ.ά.
Έκδοση: (2024-07-01)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
ανά: Jyh Yung Hor, κ.ά.
Έκδοση: (2020-06-01)

Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder
ανά: Benjamin Osborne, κ.ά.
Έκδοση: (2024-04-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
ανά: Pittock, S, κ.ά.
Έκδοση: (2019)

Case report: Identification of Hepatitis B Virus in the cerebrospinal fluid of neuromyelitis optica spectrum disorders and successful treatment with ofatumumab and inebilizumab
ανά: Linjun Cai, κ.ά.
Έκδοση: (2024-02-01)

Atypical presentations of neuromyelitis optica
ανά: Douglas Sato, κ.ά.
Έκδοση: (2011-10-01)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
ανά: Collongues, N, κ.ά.
Έκδοση: (2013)

A case report of AQP4-IgG-seropositive refractory neuromyelitis optica spectrum disorder patient with Sjögren’s syndrome and pancytopenia treated with inebilizumab
ανά: Shasha Li, κ.ά.
Έκδοση: (2024-06-01)

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
ανά: Jeffrey L. Bennett, κ.ά.
Έκδοση: (2024-10-01)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
ανά: Fujihara, K, κ.ά.
Έκδοση: (2014)

Treatment of neuromyelitis optica: an evidence based review
ανά: Douglas Sato, κ.ά.
Έκδοση: (2012-01-01)

Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
ανά: Xiaoqian Song, κ.ά.
Έκδοση: (2025-01-01)

Neuromyelitis Optica
ανά: Goyal V, κ.ά.
Έκδοση: (2009-10-01)

Neuromyelitis optica
ανά: Jacob Anu, κ.ά.
Έκδοση: (2007-01-01)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
ανά: Achim Berthele, κ.ά.
Έκδοση: (2023-04-01)

Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications
ανά: Romain Marignier, κ.ά.
Έκδοση: (2010-09-01)

Differential diagnosis of neuromyelitis optica spectrum disorders
ανά: Sung-Min Kim, κ.ά.
Έκδοση: (2017-07-01)

Racial differences in neuromyelitis optica spectrum disorder
ανά: Kim, S, κ.ά.
Έκδοση: (2018)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
ανά: Laurie Baert, κ.ά.
Έκδοση: (2021-08-01)

The borderland of neuromyelitis optica.
ανά: Matthews, L, κ.ά.
Έκδοση: (2009)

Pregnancy and neuromyelitis optica
ανά: Qiu-ying MA, κ.ά.
Έκδοση: (2016-10-01)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
ανά: Kim, W, κ.ά.
Έκδοση: (2012)

The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
ανά: Philippe Nicolas, κ.ά.
Έκδοση: (2019-11-01)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
ανά: Mealy, M, κ.ά.
Έκδοση: (2014)

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder
ανά: Stacey L. Clardy, κ.ά.
Έκδοση: (2024-05-01)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
ανά: Douglas Kazutoshi Sato, κ.ά.
Έκδοση: (2014-06-01)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
ανά: Paul, F, κ.ά.
Έκδοση: (2007)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
ανά: Friedemann Paul, κ.ά.
Έκδοση: (2007-04-01)

Use of mitoxantrone in neuromyelitis optica.
ανά: Kitley, J, κ.ά.
Έκδοση: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
ανά: Elsone, L, κ.ά.
Έκδοση: (2012)

Prognosis of Relapsing Neuromyelitis Optica
ανά: J Gordon Millichap
Έκδοση: (2003-03-01)

Neuromyelitis optica spectrum disorder
ανά: Simon Broadley, κ.ά.
Έκδοση: (2017-09-01)

Neuromyelitis Optica: Case Report
ανά: Deniz Tuncel, κ.ά.
Έκδοση: (2008-06-01)

Autoantibodies in patients with neuromyelitis optica
ανά: Xin FAN, κ.ά.
Έκδοση: (2016-10-01)